Spero Therapeutics Inc (NASDAQ:SPRO) Expected to Announce Earnings of -$1.04 Per Share

Share on StockTwits

Brokerages forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will report ($1.04) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Spero Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.23) and the highest estimate coming in at ($0.92). Spero Therapeutics reported earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 73.3%. The business is expected to issue its next earnings report on Thursday, March 12th.

On average, analysts expect that Spero Therapeutics will report full year earnings of ($3.11) per share for the current fiscal year, with EPS estimates ranging from ($3.34) to ($2.94). For the next year, analysts expect that the company will post earnings of ($3.65) per share, with EPS estimates ranging from ($5.27) to ($3.01). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.10). The firm had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $2.03 million. Spero Therapeutics had a negative return on equity of 43.10% and a negative net margin of 287.11%.

SPRO has been the topic of a number of research reports. Janney Montgomery Scott initiated coverage on Spero Therapeutics in a research note on Monday, September 9th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Spero Therapeutics in a research note on Wednesday. Oppenheimer dropped their price target on Spero Therapeutics from $30.00 to $20.00 in a research note on Wednesday, October 2nd. Zacks Investment Research downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, ValuEngine downgraded Spero Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $23.50.

Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in Spero Therapeutics during the second quarter worth $25,000. Marshall Wace LLP acquired a new position in Spero Therapeutics during the first quarter worth $39,000. D.A. Davidson & CO. acquired a new position in Spero Therapeutics during the second quarter worth $115,000. Stifel Financial Corp acquired a new position in Spero Therapeutics during the third quarter worth $137,000. Finally, Wells Fargo & Company MN raised its holdings in Spero Therapeutics by 187.9% during the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after purchasing an additional 8,915 shares during the last quarter. 48.36% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:SPRO traded up $0.17 during mid-day trading on Friday, reaching $11.09. 59,684 shares of the stock were exchanged, compared to its average volume of 48,266. The company has a 50 day simple moving average of $10.99 and a 200-day simple moving average of $10.85. The stock has a market capitalization of $210.60 million, a P/E ratio of -4.27 and a beta of 2.10. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Story: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.